Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Achieves Research Milestone in Collaboration with Roche for Development of Novel Synthetic Biotic to Treat Inflammatory Bowel Disease

CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced today...
August 23, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Granted FDA Fast Track Designation for SYNB1353 for the Treatment of Homocystinuria (HCU)

CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
August 11, 2022 06:58 ET | Source: Synlogic, Inc.

Synlogic Reports Second Quarter 2022 Financial Results and Provides Business Update

– Three clinical data readouts across three programs expected in H2 2022 – – PKU Phase 3 readiness activities underway for planned start in H1 2023 – – $106.8 million in cash, cash equivalents and...
July 28, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces Second Quarter 2022 Conference Call and Webcast

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
July 12, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria (HCU)

Expected data in H2 2022 brings Synlogic to three clinical readouts this year Third candidate in less than two years to enter the clinic; Reflects productivity of Synthetic Biotic platform ...
June 29, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces Appointment of General Counsel and Corporate Secretary

CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
June 21, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic to Present at the 2022 HCU Network America, Organic Acidemia Association and Propionic Acidemia Foundation Conference

BETHESDA, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
June 01, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Reminds Stockholders of 2022 Annual General Meeting Details

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
May 05, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces First Quarter 2022 Conference Call and Webcast

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
April 28, 2022 07:00 ET | Source: Synlogic, Inc.

Synlogic Announces Data Presentations at the 2022 Genetic Metabolic Dieticians International (GMDI) Conference and Garrod Symposium

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right